Abstract
In contrast to randomised clinical trials, open-label studies have suggested that B cell depletion by a course of rituximab is associated with a significant clinical benefit. Our aim was to assess the safety and efficacy of rituximab in 15 refractory lupus patients, particularly those with more than one course of therapy. Disease activity was measured by the classic British Isles Lupus Assessment Group (BILAG) index, anti-DNA antibodies and complement levels. We assessed immunoglobulin levels, functional antibodies and serious adverse events. The mean patient age ± SD was 37.9 ± 7.2 years and mean disease duration was 8.5 ± 3.3 years; 46 % were Afro-Caribbean, 27 % South Asian, 20 % Caucasian and 7 % others. Twelve patients responded by 6 months; six avoided major flare for >1 year. Complete absence of disease activity (BILAG D/E) lasted for 5.5 (SD 3.8) months and 4.8 (SD 3.6) months after the first (n = 15) and second (n = 9) rituximab course, respectively. The mean 6-month reduction in daily prednisolone was 10.4 (SD 11.4) mg/day and 10.7 (SD 9.3) mg/day from baseline after the first and second course, respectively. Patients with low C3/C4 normalised their C3 by 6 months. Most patients with raised anti-dsDNA normalised after rituximab courses. Serious adverse events only occurred after more than four courses of rituximab. Rituximab was safe and efficacious for treating patients with refractory systemic lupus erythematosus (SLE) and was associated with significant steroid reduction, but more than four courses of rituximab was associated with an increased risk of serious infection in two patients.
Similar content being viewed by others
References
Rahman A, Isenberg DA (2008) Systemic lupus erythematosus. N Engl J Med 358(9):929–939
Papadimitraki ED, Boumpas DT (2007) Cytotoxic drug treatment. In. Systemic lupus erythematosus, 1 edn., pp 498–510
Pescovitz MD (2006) Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Am J Transplant 6(5 Pt 1):859–866
Reynolds JA, Toescu V, Yee CS, Prabu A, Situnayake D, Gordon C (2009) Effects of rituximab on resistant SLE disease including lung involvement. Lupus 18(1):67–73
Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25(11):1271–1277
Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40(9):1725
Hay EM, Bacon PA, Gordon C, Isenberg DA, Maddison P, Snaith ML, Symmons DP, Viner N, Zoma A (1993) The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 86(7):447–458
Isenberg DA, Gordon C (2000) From BILAG to BLIPS—disease activity assessment in lupus past, present and future. Lupus 9(9):651–654
Cresswell L, Yee CS, Farewell V, Rahman A, Teh LS, Griffiths B, Bruce IN, Ahmad Y, Prabu A, Akil M, McHugh N, Toescu V, D’Cruz D, Khamashta MA, Maddison P, Isenberg DA, Gordon C (2009) Numerical scoring for the Classic BILAG index. Rheumatology (Oxford) 48(12):1548–1552
Turner-Stokes T, Lu TY, Ehrenstein MR, Giles I, Rahman A, Isenberg DA (2011) The efficacy of repeated treatment with B-cell depletion therapy in systemic lupus erythematosus: an evaluation. Rheumatology (Oxford) 50(8):1401–1408
Yee CS, Farewell V, Isenberg DA, Griffiths B, Teh LS, Bruce IN, Ahmad Y, Rahman A, Prabu A, Akil M, McHugh N, Edwards C, D’Cruz D, Khamashta MA, Maddison P, Gordon C (2009) The BILAG-2004 index is sensitive to change for assessment of SLE disease activity. Rheumatology (Oxford) 48(6):691–695
Terrier B, Amoura Z, Ravaud P, Hachulla E, Jouenne R, Combe B, Bonnet C, Cacoub P, Cantagrel A, de Bandt M, Fain O, Fautrel B, Gaudin P, Godeau B, Harle JR, Hot A, Kahn JE, Lambotte O, Larroche C, Leone J, Meyer O, Pallot-Prades B, Pertuiset E, Quartier P, Schaerverbeke T, Sibilia J, Somogyi A, Soubrier M, Vignon E, Bader-Meunier B, Mariette X, Gottenberg JE (2010) Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum 62(8):2458–2466
Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, Utset TO, Gordon C, Isenberg DA, Hsieh HJ, Zhang D, Brunetta PG (2010) Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 62(1):222–233
Fernandez-Nebro A, de la Fuente JL, Carreno L, Izquierdo MG, Tomero E, Rua-Figueroa I, Hernandez-Cruz BE, Narvaez J, Ucar E, Olive A, Zea A, Fernandez-Castro M, Raya-Alvarez E, Pego-Reigosa JM, Freire M, Martinez-Taboada VM, Perez-Venegas J, Sanchez-Atrio AI, Villa-Blanco I, Manrique-Arija S, Lopez-Longo FJ, Carreira PE, Martinez-Perez R, Garcia-Vicuna R (2012) Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: the LESIMAB study. Lupus 21(10):1063–1076
Molloy ES, Calabrese LH (2012) Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies. Arthritis Rheum 64(9):3043–3051
Tan CS, Koralnik IJ (2010) Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 9(4):425–437
Tavazzi E, Ferrante P, Khalili K (2011) Progressive multifocal leukoencephalopathy: an unexpected complication of modern therapeutic monoclonal antibody therapies. Clin Microbiol Infect 17(12):1776–1780. doi:10.1111/j.1469-0691.2011.03653.x
Lu TY, Ng KP, Cambridge G, Leandro MJ, Edwards JC, Ehrenstein M, Isenberg DA (2009) A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum 61(4):482–487
Tahir H, Rohrer J, Bhatia A, Wegener WA, Isenberg DA (2005) Humanized anti-CD20 monoclonal antibody in the treatment of severe resistant systemic lupus erythematosus in a patient with antibodies against rituximab. Rheumatology (Oxford) 44(4):561–562
Vital EM, Dass S, Buch MH, Henshaw K, Pease CT, Martin MF, Ponchel F, Rawstron AC, Emery P (2011) B cell biomarkers of rituximab responses in systemic lupus erythematosus. Arthritis Rheum 63(10):3038–3047
Marco H, Smith RM, Jones RB, Guerry MJ, Catapano F, Burns S, Chaudhry AN, Smith KG, Jayne DR (2014) The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease. BMC Musculoskelet Disord 15:178
Ramos-Casals M, Soto MJ, Cuadrado MJ, Khamashta MA (2009) Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases. Lupus 18(9):767–776
Ezeonyeji AN, Isenberg DA (2012) Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients: a steroid-sparing regimen. Rheumatology (Oxford) 51(3):476–481
Li EK, Tam LS, Zhu TY, Li M, Kwok CL, Li TK, Leung YY, Wong KC, Szeto CC (2009) Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis? Rheumatology (Oxford) 48(8):892–898
Cobo-Ibanez T, Loza-Santamaria E, Pego-Reigosa JM, Marques AO, Rua-Figueroa I, Fernandez-Nebro A, Caliz RC, Lopez Longo FJ, Munoz-Fernandez S (2014) Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: a systematic review. Seminars in arthritis and rheumatism
Favas C, Isenberg DA (2009) B-cell-depletion therapy in SLE—what are the current prospects for its acceptance? Nat Rev Rheumatol 5(12):711–716
Furie R, Looney RJ, Rovin B, Latinis, Kevin M, Appel G, Sanchez-Guerrero J (2009) Efficacy and safety of rituximab in subjects with active proliferative lupus nephritis (LN): results from the randomized, double-blind phase III LUNAR study [abstract]. Arthritis Rheum 60(Suppl 10):1149
Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, Maciuca R, Zhang D, Garg JP, Brunetta P, Appel G (2012) Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 64(4):1215–1226
Reddy V, Jayne D, Close D, Isenberg D (2013) B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design. Arthritis Res Ther 15(Suppl 1):S2
Merrill J, Buyon J, Furie R, Latinis K, Gordon C, Hsieh HJ, Brunetta P (2011) Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER). Lupus 20(7):709–716
Wofsy D, Hillson JL, Diamond B (2012) Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions. Arthritis Rheum 64(11):3660–3665
Mysler EF, Spindler AJ, Guzman R, Bijl M, Jayne D, Furie RA, Houssiau FA, Drappa J, Close D, Maciuca R, Rao K, Shahdad S, Brunetta P (2013) Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. Arthritis Rheum 65(9):2368–2379
Funding
This study was funded by Lupus UK.
Conflict of interest
R. Hickman, R. Hira-Kazal and V. Toescu declare no conflict of interest. C. Yee is a consultant for Genentech, Roche Pharmaceuticals. C. Gordon is a consultant for Genentech, Roche Pharmaceuticals and Biogen.
Author information
Authors and Affiliations
Corresponding author
Additional information
R. A. Hickman and R. Hira-Kazal contributed equally to this paper.
Rights and permissions
About this article
Cite this article
Hickman, R.A., Hira-Kazal, R., Yee, CS. et al. The efficacy and safety of rituximab in a chart review study of 15 patients with systemic lupus erythematosus. Clin Rheumatol 34, 263–271 (2015). https://doi.org/10.1007/s10067-014-2839-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-014-2839-0